Screening for bladder cancer: Theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue SUPPL.218, 2008, Pages 191-212

  Kakizoe, Tadao ^a   Mucci, Lorelei A ^b   Albertsen, Peter C ^c   Droller, Michael J ^d  

^a NATIONAL CANCER CENTER   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Natural hisotry; Screening; Urothelial carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLADDER CANCER; CANCER INVASION; CANCER MORTALITY; CANCER SCREENING; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; BLADDER TUMOR; HEALTH; MASS SCREENING; METHODOLOGY; REVIEW; THEORETICAL MODEL; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; HUMANS; MASS SCREENING; MODELS, THEORETICAL; MORBIDITY; URINARY BLADDER NEOPLASMS; WORLD HEALTH;

EID: 52949084354     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/03008880802284936     Document Type: Conference Paper

References (81)

1. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Papers 1968;34:1-163.
2. Hulka BS. Cancer screening: degrees of proof and practical application. Cancer 1988;62(8 Suppl):1776-80.
3. Grossman HB, Moyad MM, Stenzl A. Prevention, potential reversal and budgetary considerations in the screening and treatment of urothelial bladder cancer. Scand J Urol Nephrol 2008;42(Suppl 218):213-33.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001;94:153-6.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics,. CA Cancer J Clin 2007;57:43-66.
6. Fleshner N, Kondylis F. Demographics and epidemiology of urothelial cancer of the urinary bladder. In: Droller MJ, editor. American Cancer Society atlas of clinical oncology: urothelial tumors. Hamilton, Ontario: BC Decker; 2004. p. 1-16.
7. Droller MJ. Bladder cancer. Curr Prob Surg 1981;18:205-79.
8. Droller MJ. Transitional cell cancer: upper tracts and bladder. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, editors. Campbell's urology. 5th ed. Philadelphia, PA: WB Saunders; 1986. p 1343-440.
9. Messing EM, Catalona WJ. Bladder cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology. 7th ed. Philadelphia, PA: WB Saunders; 1998. p 2327-410.
10. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. Semin Urol 1993;11:177-92.
11. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-7.
12. Prout GR, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol 1992;148:1413-9.
13. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995;153:564-72.
14. Althausen AF, Prout GR Jr, Daly JJ. Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-80.
15. Kakizoe T, Matumoto K, Nishio Y, Ohtani M, Kishi K. Significance of carcinoma in situ and dysplasia in association with bladder cancer. J Urol 1985;133:395-9.
16. Kaye RW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1982;128:31-4.
17. Prout GR Jr, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979;43:2532-8.
18. Droller MJ. Natural history of stages Ta, T1 and Tis urothelial cancer in the urinary bladder. In: Lerner SP, Schoenberg MP, Sternberg CN, editors. Textbook of bladder cancer. Abingdon: Taylor and Francis; 2006. p. 267-80.
19. Kakizoe T, Tobisu K, Takai K, Tanaka Y, Kishi K, Teshima S. Relationship between papillary and nodular transitional cell carcinoma in the human urinary bladder. Cancer Res 1988;48:2293-303.
20. Spruck CH III, Ohneseit PF, Gonzales-Zulueta R, Esrig D, Miyao N, Tsai YC. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
21. Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin PP, et al. Ta and T1 bladder cancer: location, recurrence, and progression. Br J Urol 1982;54:152-7.
22. Abel PO, Hall RR, Williams G. Should pT1 transitional cell carcinoma of the bladder still be classified as superficial? Br J Urol 1988;62:235-40.
23. Holmäng S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-6.
24. Farrow GM, Utz DC. Observations on microinvasive transitional cell carcinoma of the urinary bladder. Clin Oncol 1982;1:609-14.
25. Melicow M. Histologic study of vesical epithelium intervening between gross neoplasms in total cystectomy. J Urol 1952;68:261-7.
26. Sugano K, Kakizoe T. Genetic alterations in bladder cancer and their clinical application in molecular tumor staging. Nature Urol Pract 2006;3:642-52.
27. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes FA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
28. Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326:737-40.
29. Lunec J, Challen C, Wright C, Mellon K, Neal DE. c-erb-B-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 1992;339:439-40.
30. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087-8.
31. Welden TE, Soloway MS. Susceptibility of urothelium to neoplastic cellular implantation. Urology 1975;5:824-8.
32. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III multicenter comparison of hexaminolevulinomate (HAL) fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7.
33. Sylvester RJ, Oosterlinck W, van der Meijden A. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90.
34. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin N Am 1992;19:573-80.
35. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effects of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 1996;155:1233-8.
36. Burger M, Catto J, van Oers J, Zwarthoff E, Hamdy FC, Meuth M, et al. Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper tract. Verh Dtsch Ges Pathol 2006;90:244-50.
37. Cordon-Cardo C, Sheinfeld J, Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 1997;13:319-27.
38. European Association of Urology. Guidelines on TaT1 (non-muscle invasive) bladder cancer. http:/www.uroweb.org/fileadmin/user_upload/guidelines/ 05%20TaT1%20Bladder%20Cancer.pdf; Guidelines on bladder cancer (muscleinvasive and metastatic bladder cancer). http:/www.uroweb.org/fileadmin/user_upload/ guideines/0.6%20Bladder%20Cancer.pdf
39. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74-6.
40. Schips L, Augustin H, Zigeuner RE, Gallé G, Habermann H, Trummer H, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-3.
41. Cookson MA, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
42. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164:685-9.
43. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809-18.
44. Morrison AS. Screening. In: Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998.
45. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-72.
46. Mahe C, Gaffkin L. Screening test accuracy studies: how valid are our conclusions? Application to visual inspection methods for cervical screening. Cancer Causes Control 2005;16:657-66.
47. Seed CR, Margaritis AR, Bolton WV, Kiely P, Parker S, Piscitelli L. Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion 2003;43:226-34.
48. Tabar L, Faberberg G, Day NE, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987;55:547-51.
49. Alibhai SM. Cancer screening: the importance of outcome measures. Crit Rev Oncol Hematol 2006;57:215-24.
50. Rembold CM. Number needed to screen: development of a statistic for disease screening. Br Med J 1998;317:307-12.
51. M0orrison AS. The effects of early treatment, lead time, and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982;11:261-7.
52. Walter SD, Day NE. Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 1983;118:865-6.
53. Patz EF, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000;343:1627-33.
54. Paci E, Alexander FE. Study design of randomized controlled clinical trials of breast cancer screening. J Natl Cancer Inst Monogr 1997;22:21-5.
55. Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 2004;96:1083-94.
56. Cronin KA, Weed DL, Connor RJ, Prorok PC. Case-control studies of cancer screening: theory and practice. J Natl Cancer Inst 1998;90:498-504.
57. Weiss NS, McKnight B, Stevens NG. Approaches to the analysis of case-control studies of the efficacy of screening for cancer. Am J Epidemiol 1992;135:817-23.
58. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006;107:2173-9.
59. Britton JP, Dowell AC, Whelan P, Harris PM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992;143:788-90.
60. Messing EM, Young TB, Hunt VB, Wehbie JM, Rust P. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer 1989;64:2361-7.
61. Chao D, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol 2001;3:85-93.
62. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analysis. Urology 2003;61:109-18.
63. Nasuti JF, Gomella LG, Ismial M, Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 1999;21:27-9.
64. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point of care proteomic assay. JAMA 2005;293:810-6.
65. Nguyen CT, Jones JS. Defining the role of NMP22 in bladder cancer surveillance. World J Urol 2008;26:51-8.
66. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176:919-26.
67. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, et al. Bladder tumor markers beyond cytology: international Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35-63.
68. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003;23:41-8.
69. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Molec Diagn 2000;2:116-23.
70. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systemic review. Eur Urol 2005;47:736-48.
71. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 2008;26:39-44.
72. Schmitz-Drager BJ, Tirsar L-A, Schmitz-Drager C, Dörsam J, Mellan Z, Bismarck E, et al. Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol 2008;26:31-7.
73. Marsh GM, Cassidy LD. The Drake Health Registry Study: findings from fifteen years of continuous bladder screening. Am J Ind Med 2003;43:142-8.
74. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
75. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407-13.
76. Dall'era MA, Evans CP. Tumor markers. In: Carroll PR, Grossfeld GD, editors. American Cancer Society atlas of clinical oncology: prostate cancer. Hamilton, Ontario: BC Decker; 2002. p. 93-112.
77. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
78. Klotz L. Active surveillance for genitourinary cancer: an overview. Urol Oncol Semin Orig Invest 2006;24:44-5.
79. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW. Urinary and sexual function after radical prostatectomy of clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-60.
80. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, et al. Health outcomes after external beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:2517-26.
81. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen blood testing. JAMA 1993;270:948-54.